Author information:
(1)Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, 
United Kingdom; Faculty of Health and Life Sciences, Northumbria University, 
Newcastle upon Tyne, United Kingdom. Electronic address: 
simon.bridge@northumbria.ac.uk.
(2)Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, 
United Kingdom; Institute of Translational & Stratified Medicine, Plymouth 
University Peninsula School of Medicine & Dentistry, United Kingdom.
(3)Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, 
United Kingdom; Inserm U1110, University of Strasbourg and Center for Liver and 
Digestive Diseases, Strasbourg University Hospitals, 3 Rue Koeberlé, F-67000 
Strasbourg, France.
(4)Liver Unit, Department of Medicine, Imperial College London, St Mary's 
Hospital Campus, Praed Street, London, United Kingdom.
(5)Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, 
United Kingdom.
(6)Faculty of Health and Life Sciences, Northumbria University, Newcastle upon 
Tyne, United Kingdom.
(7)Hyperlipidemia and Atherosclerosis Research Group, Clinical Research 
Institute of Montréal (IRCM), Montréal, Canada; University of Montréal, 
Montréal, Canada.
(8)Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of 
Montréal, Montréal, Canada; University of Montréal, Montréal, Canada.
(9)Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, 
United Kingdom; Department of Clinical Biochemistry, Newcastle upon Tyne 
Hospitals NHS Foundation Trust, Royal Victoria Infirmary, United Kingdom.
(10)Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, 
United Kingdom. Electronic address: margaret.bassendine@newcastle.ac.uk.